| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 800001 | 25 ug | $145 | ||
| 800002 | 100 ug | $295 |
| Application | ELISA, BLI |
|---|---|
| Format | Liquid, Purified |
| Expression Host | HEK293 |
| Target Name | CD38, T10, cADPr 1 |
| Species | Human |
| Sources | Human CD38 protein (Val43-Ile300) with C-terminus His tag and Avi tag is expressed in HEK293 cells. |
| Accession Number | P28907 |
| Molecular Weight | The 285 amino acid protein has a predicted molecular weight of 33 kDa. The protein migrates at approximately 35-45 kDa on SDS-PAGE with DTT-reduced conditions. |
| Affinity Tag | C-His-Avi |
| Purity | >95% based on SDS-PAGE under reducing condition |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.22 µm filtered |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability. |
CD38 is a multifunctional cell surface glycoprotein that plays important roles in immune cell signaling, metabolism, and cell-cell interactions. It is widely expressed on hematopoietic cells, including plasma cells, activated T and B lymphocytes, natural killer (NK) cells, monocytes, and dendritic cells, with expression levels varying depending on cell type and activation state. CD38 is also found on non-hematopoietic tissues, reflecting its broad biological significance.
Structurally, CD38 is a type II transmembrane protein with a short N-terminal cytoplasmic tail, a single transmembrane domain, and a large extracellular C-terminal domain that contains its enzymatic active site. Unlike many CD molecules that function solely as receptors or adhesion molecules, CD38 exhibits ectoenzyme activity. It acts primarily as a NAD⁺ glycohydrolase, catalyzing the conversion of nicotinamide adenine dinucleotide (NAD⁺) into metabolites such as cyclic ADP-ribose (cADPR), ADP-ribose, and nicotinic acid adenine dinucleotide phosphate (NAADP).
Functionally, CD38 regulates intracellular calcium signaling through the generation of cADPR and NAADP, which act as second messengers controlling calcium release from intracellular stores. Through this mechanism, CD38 influences cell activation, proliferation, migration, cytokine secretion, and survival. CD38 also participates in cell-cell interactions by associating with other surface molecules and contributing to immunological synapse formation. CD38 has several functional ligands, most notably CD31 (PECAM-1), which mediates adhesion and signaling interactions between immune cells and endothelial cells. In addition, CD38’s enzymatic substrates, such as NAD⁺, serve as functional ligands that drive its metabolic activity. These interactions integrate immune signaling with cellular metabolism, particularly in inflamed or metabolically stressed environments.
Aberrant CD38 expression and activity are implicated in multiple diseases. CD38 is highly expressed on malignant plasma cells in multiple myeloma and on certain leukemias and lymphomas, making it a valuable diagnostic marker. Elevated CD38 expression is also associated with chronic inflammation, immune exhaustion, and aging, partly due to its role in NAD⁺ depletion. In autoimmune and infectious diseases, altered CD38 expression reflects immune activation and disease progression.
CD38 is a major therapeutic target, particularly in hematologic malignancies. Monoclonal antibodies targeting CD38 have transformed the treatment of multiple myeloma by inducing tumor cell death through antibody-dependent cellular cytotoxicity, complement activation, and immune modulation. Beyond oncology, strategies aimed at modulating CD38 enzymatic activity are being explored to restore NAD⁺ levels and improve immune or metabolic function, highlighting CD38’s growing importance in both immunotherapy and metabolic intervention.
Human CD38 Protein (C-His-Avi) TDS
Anti-Human CD19 Antibody, Clone HIB19
iF560 Anti-Human CD19 Antibody, Clone HIB19
iF647 Anti-Human CD19 Antibody, Clone 019AM2b
Biotin Anti-Human CD19 Antibody, Clone 019AM2b
Anti-Human CD38 Antibody, Clone HIT2
iF647 Anti-Human CD38 Antibody, Clone HIT2
Anti-Human CD38 (Daratumumab Biosimilar), Clone Daratumumab
Anti-Human CD38 (Isatuximab Biosimilar), Clone Isatuximab
Biotin Human CD38 Protein (C-His-Avi)
Have a product or application question? Consult our FAQs or contact us.
